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Abstract
Disease-related malnutrition (DRM) is a frequent clinical problem 
and is characterized by loss of lean body mass, and decreased 
function including muscle function and immunocompetence. In 
DRM, nutritional intervention is necessary, but it has not consistently 
been shown to be sufficient. Other factors, e.g., physical activity 
and hormonal/metabolic influencers of the internal milieu, are also 
important in the treatment of DRM. A prerequisite for successful 
treatment of DRM is the positive balance between anabolism and 
catabolism. We propose to approach DRM using this paradigm of 
anabolic competence, for conceptual and practical reasons. Anabolic 
competence is defined as “that state which optimally supports 
protein synthesis and lean body mass, global aspects of muscle 
and organ function, and immune response.” Anabolic competence 
and interdisciplinary, multimodality interventions create a practical 
foundation to approach DRM in a proactive comprehensive way. 
In this narrative review we describe the paradigm of anabolic 
competence, and its operationalization by measuring factors related 
to anabolic competence and suited for clinical management of 
patients with DRM.
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INTRODUCTION
Disease-related malnutrition (DRM) is frequent in clinical settings 
[1,2]. Malnutrition is defined as “a state resulting from lack of 
intake or uptake of nutrition that leads to altered body composition 
(decreased fat-free mass) and body cell mass leading to diminished 
physical and mental function and impaired clinical outcome from 
disease” [3]. DRM can lead to increased risk of complications, e.g., 
impaired wound healing, increased length of hospital stay, and 
higher mortality [1,4]. Utilization and efficacy of nutrients is affected 
by several factors including physical (in)activity and hormonal/
metabolic influences of patient internal milieu, which includes 
inflammation. Treatment of DRM must, therefore, not only optimize 
nutritional intake, but also  address broad anabolic or anticatabolic 
factors [5].
To this purpose, it would be useful to consider DRM from the 
perspective of anabolic competence. Anabolic competence has been 
defined as “that state which optimally supports protein synthesis and 
lean body mass, global aspects of muscle and organ function, and 
immune response” [6]. The paradigm of anabolic competence was 
developed to facilitate a comprehensive and practical interdisciplinary 
multimodality approach that could be used to address malnutrition 
and lean body mass/function deficit. Within this paradigm, factors 
identified as being involved in anabolic competence were categorized 
into three domains: “nutritional milieu”, “exercise”, and “hormonal 
milieu” [6]. Here we use a revised model (Figure 1), which includes 
the broader term “physical activity” that addresses both exercise 
and daily activity, since all forms of activity contribute to support 
anabolic competence. Moreover, instead of “hormonal milieu”, the 
term “internal milieu” will be used, which includes hormones, but 
also other neuroendocrine regulators, inflammatory factors, and the 
adverse effects of disease treatment (e.g., chemotherapy, radiation, 
corticosteroids), which can affect anabolic competence.
Standardized, reliable, and proactive assessment and monitoring 
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are required to determine the degree of anabolic (in)competence. 
Moreover, within the paradigm of anabolic competence, the patient’s 
nutritional status is evaluated from a dynamic perspective, whereas 
DRM is usually considered as a static state, which ignores the 
possibility of anabolism despite absolute muscle mass/function 
deficit. For example, a patient may have lost 15% weight in the past 
six months, but may have regained 2% weight in the past month, 
indicating anabolism rather than ongoing catabolism, despite the 
13% net weight loss. Therefore, the shape of the weight curve and 
the rate of weight change are critical in understanding the progression 
of reversal of DRM. The Patient-Generated Subjective Global 
Assessment (PG-SGA), widely used to screen/assess nutritional 
risk or deficit, captures the underlying dynamic processes and core 
components of intervention supporting anabolic competence [7].
In this narrative review, we describe the modifiable factors 
contributing to support of anabolic competence, and how these 
factors can be assessed and monitored to better match with clinical 
intervention practice.
Figure 1. The three domains of anabolic competence, adapted from ©Ottery 
FD, 1998, 2002.
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NUTRITION
Optimal intake of macro- and micronutrients is essential for 
maintenance of metabolic equilibrium. Hence, nutritional interventions 
form the core of treatment strategies aimed at promoting anabolism 
and/or counteracting catabolism. Protein is critical for anabolism as 
substrate for tissue synthesis. To meet metabolic demands necessary 
to maintain normal body composition in a healthy individual, the 
World Health Organization (WHO) recommends a daily protein 
intake of 0.8 g/kg BW/day [8]. Higher protein intake of ≥1.0 g/kg 
BW/day is recommended for individuals aged >65 years, to account 
for age-related muscle tissue degradation [9]. In patients with DRM, 
nutrient requirements is even higher, due to effects of the disease, 
generally indicated as the “inflammatory milieu”. This may increase 
resting energy expenditure and nitrogen excretion, indicating higher 
protein requirements [10]. Protein intake of 1.2-1.5 g/kg BW/day, 
as recommended in cancer patients, is generally recommended in 
malnourished patients [11,12]. Protein requirements of critically ill 
patients are considered to be as high as 1.2-2.0 g/kg BW/day, and 
potentially higher for patients with burn injuries or multi-trauma 
[13]. Additionally, some studies suggest that in older adults the 
distribution of protein intake throughout the day may be important 
in promotion of maximal protein synthesis response per meal [14].
There is evidence that specific nutrients can elicit anabolic responses 
directly. Certain branched-chain amino acids, in particular leucine, 
may directly trigger an anabolic response through the Mechanistic 
Target of Rapamycin (mTOR) pathway [15]. Nevertheless, sufficient 
bioavailability of all other amino acid precursors for protein 
synthesis remains imperative to obtain a relevant increase in protein 
synthesis [16]. Furthermore, increasing evidence supports the 
positive role of n-3 polyunsaturated fatty acid (PUFA) in the anabolic 
response. Particularly in older adults, n-3 PUFA supplementation has 
demonstrated to increase post-exercise and post-absorptive protein 
synthesis and to improve muscle strength [17–19]. The exact 
mechanisms for this beneficial effect on protein synthesis remains to 
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be determined. The effect seems to occur independently of the anti-
inflammatory properties of n-3 PUFA, considering that inflammatory 
markers remained unchanged after n-3 PUFA supplementation in 
presence of significantly increased protein synthesis [17].
Sufficient protein intake does not independently determine the 
utilization of proteins. Importantly, nutritional intake does not equal 
nutrient bioavailability. Digestion and absorption of protein relies 
on several factors, including the composition and digestibility of the 
proteins, other dietary constituents, gastric motility, gastric pH, small 
intestinal transit time, and most importantly the pancreatic protease 
secretion and activity. These factors can be negatively influenced by 
both the disease itself and by adverse effects of medication (e.g., 
corticosteroids, antianabolic agents such as megesterol acetate) or 
other therapy (e.g., radiotherapy). Both proteins and malnutrition 
itself [20] can modulate gastric emptying rate and thereupon 
modify the postprandial metabolic response. Proteins classified as 
‘fast’ could promote a higher anabolic response compared to ‘slow’ 
proteins [21]. For example, when ingested separately, whey protein 
is considered ‘fast’ as it remains soluble in the stomach, and casein 
is considered ‘slow’ as the clotting of casein reduces the stomach 
emptying rate [22]. However, gastric emptying rate of protein 
depends on total meal composition [21]. Disturbances in pancreatic 
enzyme secretion and/or activity can impair protein digestion. 
Furthermore, reductions of the intestinal absorptive surface, and 
gastro-intestinal diseases that impair intestinal absorption, e.g., 
inflammatory bowel disease, gastro-enteritis, and bowel ischemia, 
can severely reduce protein absorption [23,24]. In addition, protein 
utilization is strongly interrelated with energy balance. Protein 
synthesis not only requires energy, but protein itself can also be 
used as an energy source. Nitrogen balance studies showed that 
nitrogen retention in humans improved with increasing/adequate 
energy intake [25,26].
Finally, the complex effects of disease can greatly impair protein 
utilization, in both acute and chronic settings. Impaired utilization 
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is apparent from the incomplete therapeutic effect of nutritional 
support in DRM, as opposed to the complete therapeutic effect 
in malnutrition without disease, e.g., starvation (Figure 2) [10]. 
Impaired protein utilization in DRM indicates the need for a 
multimodality interventional strategy over a “protein-energy-only” 
strategy, taking also into account the other components contributing 
to anabolic competence . The specifi c effects of different disease 
states on nutrient intake, uptake and utilization can differ between 
and within patients, and vary with disease severity. Therefore, the 
management of DRM requires a personalized and dynamic approach.
Figure 2. Hypothetical relationship of the effect of nutritional support on 
lean body mass in the treatment of DRM compared to malnutrition without 
disease. Nutritional intervention alone in DRM is insuffi cient to maintain or 
recover lean body mass as protein utilization is impaired (left panel), 
whereas nutritional support in malnutrition without disease may be suffi cient 
to recover lean body mass (right panel). Adapted from Jensen et al. 2010 
[10].
The reduced effectiveness of nutritional interventions alone in 
DRM, versus malnutrition without disease, indicates that further 
insight into the metabolic derangements, and their effect on protein 
utilization may allow improvement in the management of DRM. 
To facilitate such further improvement, a bedside tool quantifying 
protein utilization would be useful. Although the nitrogen balance 
method, i.e., the difference between nitrogen intake and loss which 
refl ects the gain or loss of total body protein, is a good indicator of 
either anabolism or catabolism, this method is not able to provide 
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insight in changes in protein synthesis and breakdown [27]. As amino 
acids are used either for protein synthesis or are oxidized [28], a 
breath test that measures amino acid oxidation might serve as a 
non-invasive clinical tool to collect information on protein utilization 
by the body [29,30].
PHYSICAL ACTIVITY
Physical activity, i.e., daily activity and exercise, is a crucial anabolic 
trigger as it increases the utilization of ingested protein for protein 
synthesis in the body and is, therefore, a highly relevant modifiable 
factor in treatment of DRM. Although exercise was incorporated into 
the paradigm of anabolic competence almost two decades ago, it is 
just in the past decade that exercise and daily activity are fully being 
recognized as important anabolic triggers for the prevention [31] and 
treatment of disease [32]. A recent review compiled the beneficial 
effect of physical activity on clinical outcomes of 26 diseases, e.g., 
metabolic diseases, and cancer [32].
Muscle-strengthening exercise, e.g., resistance exercise and aerobic 
physical exercise, convey specific benefits contributing to anabolic 
competence [33]. Resistance exercise stimulates muscle hypertrophy 
and increases muscle strength [34]. Aerobic physical exercise 
improves maximal oxygen consumption [35], insulin sensitivity 
[36], and decreases oxidative stress [37]. Improved aerobic fitness 
increases the capacity to perform muscle-strengthening exercise 
and daily activities. This positive feedback loop further enhances 
anabolic competence, as demonstrated in elderly women [38].
Data on levels of physical activity in patients with DRM are lacking. 
In various patient populations, low levels of physical activity are 
associated with higher mortality and worse disease outcomes 
[39], probably related to, amongst others, loss of muscle mass, 
inflammation, and deranged metabolism [39,40]. Increasing 
the physical activity level in certain patient populations may be 
beneficial. For example, a 12-week randomized control trial (RCT) 
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with 130 sarcopenic elderly, in which regular controlled exercise was 
given with or without supplementation 22 g of whey protein and 
2.5 µg vitamin D, resulted in a decreased risk of malnutrition with 
both interventions, with the largest decrease found in those with 
supplementation [41]. These results demonstrate the synergistic 
effect of nutrition and physical activity on reducing malnutrition risk 
in sarcopenic elderly. Yet, RCTs that take into account all aspects of 
anabolic competence are limited.
The WHO guidelines have guided the target amount of physical 
activity in patient populations such as cancer patients [11]. Whether 
the WHO guidelines are an attainable and a realistic goal for patients 
with DRM is questionable, as the guidelines are intended for disease 
prevention rather than restoring muscle mass in patients with DRM.
As physical activity can contribute to anabolic competence, physical 
inactivity has the opposite effect. Disuse muscle atrophy, e.g., bed 
rest, has detrimental effects on muscle mass and strength [42,43]. 
Moreover, bed rest with inadequate protein ingestion can lead to 
a loss of muscle mass of ~95 g/day in healthy older adults [44]. 
For patients with DRM, any increase in physical activity, combined 
with nutrition, can contribute to their anabolic competence [12]. 
Avoidance of inactivity, as a more feasible goal in patients with DRM, 
is relevant and meaningful.
Several instruments have been developed to assess physical 
activity for research applications and may not be suited for clinical 
purposes. Common instruments to quantify physical activity and 
intensity are self-reported physical activity questionnaires (SPRAQs) 
[45]. Although SPRAQs are easy to administer, the shortfall of 
many SPRAQs is that these are less sensitive in detecting light- 
to moderate-intensity physical activity, and inquire information on 
average habitual physical activity, rather than measuring actual/
recent day-to-day physical activity [46], which is indispensable 
information for the acutely ill.
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Considering DRM, objective day-to-day measurements of physical 
activity and physical function would provide more clinically relevant 
information, which can be useful for monitoring a patient’s condition 
and to assess adherence to physical activity interventions. The need 
for such monitoring is most apparent in hospitalized patients with 
acute (or acute-on-chronic) disease, where disease state, activity, 
and nutritional status evolve from day to day.
INFLUENCERS OF INTERNAL MILIEU
In patients with DRM, the effect of ingested nutrition combined with 
physical activity on subsequent protein processing is influenced by 
hormonal/metabolic influencers of the internal milieu, including 
neuroendocrine regulation, inflammation activity, and disease 
treatment. Inflammation, lack of physical activity, and disturbed 
internal milieu hinders an anabolic response, with synergistic 
detrimental effects on muscle mass and overall anabolic competence, 
reinforcing the need for a multimodality approach.
The major molecular pathway responsible for the regulation of 
protein synthesis is mTOR and subsequent activation of mTORC1 
pathway. The mTOR pathway is activated by insulin, testosterone, 
leucine, a leucine metabolite β-hydroxy β-methylbutyric acid, and 
physical activity [47–50]. For protein degradation, the lysosomal 
pathway, the calcium-regulated calpains pathway, and the ubiquitin-
proteasome pathway have been identified. The latter is the main 
contributor to loss of muscle mass in acute and chronic disease, 
as many anabolic and catabolic signaling pathways are involved in 
the regulation of the ubiquitin-proteasome pathway genes [51]. The 
molecular mechanisms of protein synthesis and degradation are 
described elsewhere [47–49,51].
Net protein breakdown, i.e. loss of muscle mass, in DRM is mostly 
related to increased inflammation due to the disease itself, or its 
treatment, as seen in patients with sepsis, cancer, and renal failure 
[52]. Inflammation leads to loss of muscle mass by both promoting 
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catabolism and impairing anabolism in muscle. Furthermore, 
inflammation increases energy and protein requirements [10]. 
Although, inflammation-related muscle degradation is not fully 
clarified, the pro-inflammatory cytokine TNF-α is a significant 
mediator. TNF-α stimulates production of various catabolic cytokines, 
and is associated with muscle mass loss in, for example, patients 
with cancer [53]. C-reactive protein (CRP), a well-established 
marker for acute and chronic inflammation, impairs the proliferation 
of muscle cells [54], and has been associated with lower muscle 
mass in for example elderly women and patients on dialysis [54,55]. 
This suggests that inflammation reducing treatment could reduce 
the loss of muscle mass. However, RCTs are needed to confirm 
causality and effect size.
Furthermore, as hormones play an important role in physiological 
homeostasis, disturbances in the hormonal milieu can negatively 
influence anabolic competence. Leptin is produced by both adipose 
tissue and skeletal muscle, and is an important regulator in whole 
body energy homeostasis [56,57]. Leptin functions as a “satiety 
hormone”, whereas ghrelin is considered a “hunger hormone” [58]. 
Ghrelin promotes weight gain and lowers the uptake of glucose by 
reducing insulin secretion [58]. A major anabolic regulator is insulin, 
by regulating the uptake of amino acids and blood glucose into 
muscle, and regulating metabolism [59]. By indirectly activating 
the mTORC1 pathway, IGF-1 induces hypertrophy [60]. Together 
with insulin, IGF-1 and GH form an regulatory axis, which regulates 
cell apoptosis versus growth [61]. Sex steroid hormones promote 
anabolism. Exercise increases sex steroid hormone levels [62]. Low 
levels of sex steroid hormones can be increased with for example 
testosterone replacement therapy, but leads to increased risk of 
prostate cancer, stroke, and myocardial infarction [63]. Medical 
treatment of disease can disturb the internal milieu. For example, 
radiation therapy in the head and neck region including the thyroid 
gland may lead to hypothyroidism [64]. Exogenous systemic 
corticosteroids or antianabolic agents may cause decreased anabolic 
competence as well [65].
138   |
Chapter 7
Thus, as the hormonal/metabolic derangements in DRM, caused by 
the disease itself or by adverse effects of treatment, are complex 
and dynamic, monitoring is difficult. Despite associations between 
possible blood markers and risk of DRM, no simple measures have 
emerged that reliably reflect the metabolic derangements and can 
guide clinical management.
PRACTICAL AND COMPREHENSIVE ASSESS-
MENT OF ANABOLIC COMPETENCE AND DRM
As DRM is characterized by loss of lean body mass and function, 
effective treatment of DRM must result in measurable outcomes, 
such as improved lean body mass, muscle function, and immune 
function. To proactively improve a patient’s nutritional status, an 
easy and practical assessment and monitoring tool is essential. 
Assessment and monitoring requires inclusion of the domains of 
anabolic competence, as well as outcome measures for the clinical 
setting to acquire information on the current state of DRM, the 
progression of DRM, and the effect of intervention on DRM.
Despite improvements in the understanding and recognition of the 
importance of anabolic and catabolic stimuli in the development 
and reversal of DRM, the PG-SGA was specifically developed in the 
context of and operationalizes the paradigm of anabolic competence 
[7,66]. The PG-SGA has demonstrated good validity and is a bedside 
instrument to screen, assess and monitor nutritional status and risk 
factors, and can be utilized to triage for multimodality interventions 
and monitor the effect of these interventions [67]. The PG-SGA uses 
a patient-centric approach to address patient concerns and improve 
patient and healthcare professional interaction. The domains assessed 
and monitored by the PG-SGA are: 1) changes in body weight, 2) 
changes in nutritional intake, 3) symptoms which negatively influence 
intake, absorption and utilization of nutrients, 4) level of activities and 
function, 5) conditions that increase nutritional risk or requirements, 
6) metabolic stress, and 7) physical examination [66]. The PG-SGA 
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captures and provides an overview of information, generated by both 
the patient and healthcare professional, from different domains into 
one document which provides actionable information for, amongst 
others, the physician, the nurse, the dietitian, and physiotherapist, 
respectively. As such, it facilitates and enhances an interdisciplinary, 
multimodality treatment [66]. The studies available on reliability of 
the PG-SGA suggest good inter-rater reliability (90% agreement in 
PG-SGA categories between physician and dietitian [68] and good 
agreement (ICC=0.901) between dietitians [69], sufficient internal 
consistency (Cronbach’s alpha=0.722) [70], and good reproducibility 
(test-retest: r=0.866) [70]. A detailed explanation of the PG-SGA 
including its scoring, its content validity, and its good predictive 
value have been described elsewhere [66,71]. One of the potential 
barriers is that PG-SGA-naïve healthcare professionals may find the 
physical examination difficult, although comprehensible. Therefore 
training is recommended, as one day of PG-SGA training improves 
perceived difficulty and comprehensibility [72]. However, perceived 
difficulty of the physical examination part of the PG-SGA remained 
below the acceptable level after one day of training despite clear 
improvements, and therefore requires additional training and/or 
more information [74]. Another potential barrier is the perceived 
lack of time for applying the PG-SGA. However, the time needed to 
complete the patient component and the professional component 
of the PG-SGA is less than five minutes, for both patients and 
professionals, respectively [71].
DISCUSSION
Anabolic competence is vital for patients with DRM, whereby 
adequate nutrition alone does not resolve catabolism or increase 
anabolism. Net catabolism, as represented by decreasing lean body 
mass, leads to significantly compromised outcomes, and will remain 
ongoing if other complementary conditions needed for anabolic 
competence are not met. The paradigm of anabolic competence 
serves as a theoretical base, from which clinical implications can be 
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made for each of the domains of anabolic competence. The clinical 
implications are, amongst others, establishing a protein intake of 
1.2-1.5 g/kg BW/day, the encouragement of patients to stay out of 
bed or chair when possible to avoid physical inactivity, and to monitor 
influencers of the internal milieu, e.g., inflammatory activity by 
measuring change in CRP levels as a reflection of anti-inflammatory 
treatment effectiveness and adequacy of relevant hormone levels. 
In this narrative review we emphasize that, rather than solely 
concentrating on nutritional intake, other factors that determine 
anabolic competence, i.e., physical activity and influencers of 
internal milieu, are imperative for achieving and maintaining a good 
nutritional status and thus must be integrated into the assessment, 
monitoring and treatment of DRM.
Ultimately, integration of clinically relevant and practical 
measurements to assess modifiable factors contributing to anabolic 
competence could serve as the foundation for decision making and 
intervention to optimize an interdisciplinary multimodality approach, 
and could contribute to both the prevention and treatment of DRM.
Current knowledge about the separate domains involved in patients 
with DRM implicates that further research is needed towards 
monitoring the effectiveness of treatment in DRM patients aimed at 
optimizing all three domains of anabolic competence. Therefore, at 
least changes in lean body mass, muscle function, and inflammatory 
and hormonal status must be monitored.
In conclusion, we consider the paradigm of “anabolic competence” 
and its practical application as highly valuable to daily clinical 
practice. Therefore, we propose to implement the concept of 
anabolic competence in clinical practice for the treatment of DRM. 
Standardized, reliable, and practical instruments that incorporate 
the domains of anabolic competence, such as the PG-SGA, could 
help to improve the prevention, treatment, and monitoring of DRM.
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